Cullinan OncologyCGEM
About: Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
Employees: 85
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
998% more call options, than puts
Call options by funds: $3.14M | Put options by funds: $286K
131% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 26
129% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 17
100% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 6 (+3) [Q2]
59% more capital invested
Capital invested by funds: $690M [Q1] → $1.1B (+$407M) [Q2]
19% more funds holding
Funds holding: 113 [Q1] → 135 (+22) [Q2]
15.1% more ownership
Funds ownership: 94.09% [Q1] → 109.19% (+15.1%) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Wedbush Robert Driscoll 50% 1-year accuracy 30 / 60 met price target | 127%upside $36 | Outperform Reiterated | 18 Sept 2024 |
HC Wainwright & Co. Edward White 20% 1-year accuracy 24 / 118 met price target | 76%upside $28 | Buy Reiterated | 17 Sept 2024 |
HC Wainwright & Co. Edward White 20% 1-year accuracy 24 / 118 met price target | 76%upside $28 | Buy Reiterated | 16 Sept 2024 |
Wedbush Robert Driscoll 50% 1-year accuracy 30 / 60 met price target | 127%upside $36 | Outperform Reiterated | 9 Aug 2024 |